{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:15:57Z","timestamp":1784549757578,"version":"3.55.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"China National Postdoctoral Program for Innovative Talents"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Alopecia areata (AA) is an autoimmune disorder characterized by nonscarring hair loss, significantly impacting patients\u2019 quality of life. Rapid hair regrowth is the primary goal of treatment, particularly for super-responders (SRs), who demonstrate remarkable and swift improvement. The advent of Janus kinase (JAK) inhibitor treatment has transformed AA management, yet predictors of SRs in AA remain underexplored.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study aimed to characterize SRs among patients with AA treated with tofacitinib, identify clinical and demographic predictors of SRs, and analyse treatment outcomes over 12\u2005months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a single-centre, longitudinal retrospective analysis of 80 patients with AA treated with tofacitinib at Xiangya Hospital, Central South University, Changsha, China, from February 2021 to August 2024. Patients were classified as SRs if they achieved a \u2265 80% reduction in the Severity of Alopecia Tool (SALT) score by the 3rd month or a 100% reduction (SALT100) by the 6th month. Clinical data, treatment outcomes and potential predictors of SR status were analysed using binary logistic regression.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>SRs comprised 37.5% of the cohort. Significant predictors of SR status included older age and the absence of prior JAK inhibitor treatment. Female patients and those without previous corticosteroid use also trended towards higher SR rates, although these factors were not statistically significant. SRs demonstrated faster and more sustained hair regrowth, with 93% achieving SALT100 by 6\u2005months, compared with 42% of non-SRs at 12\u2005months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>To our knowledge, this study is the first to define and characterize SRs in patients with AA treated with a JAK inhibitor, providing a reference for dermatologists to optimize AA management. Identifying SRs early may improve patient outcomes and inform treatment strategies, particularly in those with a history of JAK inhibitor use. Further research is warranted to validate these findings in larger, multicentre cohorts.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llaf131","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T03:24:56Z","timestamp":1741922696000},"page":"1571-1577","source":"Crossref","is-referenced-by-count":4,"title":["Characteristics and predictive values of super-responders in alopecia areata under tofacitinib treatment: a single-centre retrospective study"],"prefix":"10.1093","volume":"50","author":[{"given":"Ruxin","family":"Ji","sequence":"first","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Hu Nan Key Laboratory of Aging Biology , Changsha ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jundong","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Hu Nan Key Laboratory of Aging Biology , Changsha ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Jian","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Hu Nan Key Laboratory of Aging Biology , Changsha ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0852-4576","authenticated-orcid":false,"given":"Min","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Hu Nan Key Laboratory of Aging Biology , Changsha ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Hu Nan Key Laboratory of Aging Biology , Changsha ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Hu Nan Key Laboratory of Aging Biology , Changsha ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Xiangya Hospital, Central South University, Hu Nan Key Laboratory of Aging Biology , Changsha ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"2025072412174483200_llaf131-B1","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jdermsci.2023.09.008","article-title":"Alopecia areata: what\u2019s new in the epidemiology, comorbidities, and pathogenesis?","volume":"112","author":"Dainichi","year":"2023","journal-title":"J Dermatol Sci"},{"key":"2025072412174483200_llaf131-B2","doi-asserted-by":"crossref","first-page":"1902420","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab effectiveness and identification of super-responders in severe asthma","volume":"55","author":"Harvey","year":"2020","journal-title":"Eur Respir J"},{"key":"2025072412174483200_llaf131-B3","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.mayocp.2015.08.017","article-title":"Characteristics of exceptional or super responders to cancer drugs","volume":"90","author":"Prasad","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"2025072412174483200_llaf131-B4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/bjd\/ljad280","article-title":"How to define a \u2018super-responder\u2019 to biologics in psoriasis studies","volume":"189","author":"Thomas","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025072412174483200_llaf131-B5","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"2025072412174483200_llaf131-B6","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","article-title":"Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial","volume":"401","author":"King","year":"2023","journal-title":"Lancet"},{"key":"2025072412174483200_llaf131-B7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/annrheumdis-2020-218398","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement","volume":"80","author":"Nash","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2025072412174483200_llaf131-B8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2025072412174483200_llaf131-B9","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v103.12425","article-title":"Effectiveness and predictive factors of response to tofacitinib therapy in 125 patients with alopecia areata: a single-centre real-world retrospective study","volume":"103","author":"Huang","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"2025072412174483200_llaf131-B10","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v103.13418","article-title":"Effectiveness of tofacitinib in pre-adolescent alopecia areata: a retrospective case series and literature review","volume":"103","author":"Huang","year":"2023","journal-title":"Acta Derm Venereol"},{"key":"2025072412174483200_llaf131-B11","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjd.18883","article-title":"The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials","volume":"183","author":"Wyrwich","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025072412174483200_llaf131-B12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/13543784.2024.2348062","article-title":"Novel investigational drugs for alopecia areata and future perspectives","volume":"33","author":"Chim","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"key":"2025072412174483200_llaf131-B13","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/bjd\/ljad253","article-title":"When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials","volume":"189","author":"King","year":"2023","journal-title":"Br J Dermatol"},{"key":"2025072412174483200_llaf131-B14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/jdv.19768","article-title":"European expert consensus statement on the systemic treatment of alopecia areata","volume":"38","author":"Rudnicka","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025072412174483200_llaf131-B15","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1080\/09546634.2021.1898528","article-title":"Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis","volume":"33","author":"Feldman","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2025072412174483200_llaf131-B16","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/jdv.18825","article-title":"Brodalumab in plaque psoriasis: real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks","volume":"37","author":"Rompoti","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025072412174483200_llaf131-B17","article-title":"Super-responders in moderate\u2013severe psoriasis under guselkumab treatment: myths, realities and future perspectives","volume":"12","author":"Ruiz-Villaverde","year":"2022","journal-title":"Life (Basel)"},{"key":"2025072412174483200_llaf131-B18","first-page":"e1321","article-title":"Super-responders in psoriasis under interleukin 23 inhibitor treatments, experience in two centres","volume":"37","author":"Men\u00e9ndez S\u00e1nchez","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025072412174483200_llaf131-B19","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/jdv.18474","article-title":"Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator\u2019s Global Assessment scores predict complete skin clearance","volume":"36","author":"Reich","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025072412174483200_llaf131-B20","doi-asserted-by":"crossref","first-page":"2331782","DOI":"10.1080\/09546634.2024.2331782","article-title":"Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: a real-life cohort study on the effectiveness and drug survival over one-year","volume":"35","author":"Liu","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"2025072412174483200_llaf131-B21","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.15489","article-title":"JAK inhibitors for alopecia areata: a systematic review and meta-analysis","volume":"33","author":"Phan","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025072412174483200_llaf131-B22","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/ajd.14325","article-title":"Real-world effectiveness and safety of tofacitinib for alopecia areata: a retrospective cohort study of 202 patients","volume":"65","author":"Cranwell","year":"2024","journal-title":"Australas J Dermatol"},{"key":"2025072412174483200_llaf131-B23","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jaad.2006.05.008","article-title":"Alopecia areata: a long term follow-up study of 191 patients","volume":"55","author":"Tosti","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2025072412174483200_llaf131-B24","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1111\/jdv.19464","article-title":"A risankizumab super responder profile identified by long-term real-life observation-IL PSO (Italian Landscape PSOriasis)","volume":"38","author":"Gargiulo","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025072412174483200_llaf131-B25","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jaad.2023.03.041","article-title":"Switching between tofacitinib and baricitinib in alopecia areata: a review of clinical response","volume":"89","author":"Kazmi","year":"2023","journal-title":"J Am Acad Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf131\/62413337\/llaf131.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/8\/1571\/62413337\/llaf131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/8\/1571\/62413337\/llaf131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T16:17:49Z","timestamp":1753373869000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/8\/1571\/8078308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":25,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,3,14]]},"published-print":{"date-parts":[[2025,7,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf131","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,3,14]]}}}